European Medicines Agency

(redirected from Committee on Orphan Medicinal Products)

European Medicines Agency

The drug regulatory agency for the European Union, which is located in London. The EMA is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the EU.
References in periodicals archive ?
M2 EQUITYBITES-July 23, 2013-NanoViricidesa[euro](tm) Orphan Drug Designation application for DengueCide to be reviewed by clinical coordinators by Committee on Orphan Medicinal Products of EMA(C)2013 M2 COMMUNICATIONS http://www.
NanoViricides Inc (OTC BB: NNVC), a development stage company creating special purpose nanomaterials for viral therapy, announced on Monday the notification by the Committee on Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA) of the appointment of a team of clinical coordinators for the purpose of reviewing the company's upcoming orphan drug designation application for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
M2 PHARMA-July 23, 2013-NanoViricidesa[euro](tm) Orphan Drug Designation application for DengueCide to be reviewed by clinical coordinators by Committee on Orphan Medicinal Products of EMA(C)2013 M2 COMMUNICATIONS

Full browser ?